Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1272

Shown on this page

Current sort

Live official records

Conditions: Childhood Medulloblastoma
Interventions: Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine; Procedure · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 21 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 106
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Month to 6 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 75
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more

Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 30 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 152
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more

Conditions: Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Seminoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions: Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Pulmonary Function Test, Questionnaire Administration; Other · Procedure · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 1,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 566
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 338 more

Conditions: AVB - Atrioventricular Block, Fetal AVB
Interventions: Dexamethasone, IVIG; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Breast Cancer
Interventions: biologic sample preservation procedure; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pleuropulmonary Blastoma
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more

Conditions: B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 39 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Madera, California + 60 more

Conditions: Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions: Cytology Specimen Collection Procedure, Medical Chart Review; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 75,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 246
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more

Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 32
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 27 more

Conditions: Arthritis, Rheumatoid
Interventions: INFINITY™ with ADAPTIS™ Technology Total Ankle System; Device
Lead sponsor: Stryker Trauma and Extremities; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 13
States / cities: Gilbert, Arizona • Rancho Mirage, California • Aurora, Colorado + 10 more

Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Tamoxifen, Anastrozole, Degarelix, Abemaciclib; Drug
Lead sponsor: Jose Pablo Leone; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Boston, Massachusetts + 6 more

About this Vanderbilt University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Vanderbilt University Medical Center

Filter and sort this campus

Live official records

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Project: Every Child for Younger Patients With Cancer

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

INFINITY™ With ADAPTIS™ Technology Study

ETHAN - ET for Male BC

About this Vanderbilt University Medical Center institution page